Figure 6. PD pathogenic LRRK2 mutations interfere with Rab-GDI1/2 association.
(A) Fold changes (T73A/T73E, n=3) of indicated MS-quantified Rab10 interactors. (B) Same as (A) but S106A-Rab12 and S106E-Rab12 (n=4). (C) Different LRRK2 versions were co-expressed with Rab8a in HEK293 cells, lysates subjected to immunoblot analysis or immunoprecipitation using α-HA antibodies and indicated signals quantified (D). (E) and (F) Same as (C) with Rab12 expression. (G) Scheme for analyzing T72A-Rab8a and T72E-Rab8a subcellular protein distributions in a SILAC experiment. (H) SILAC ratios (Log2) of T72E-Rab8a/T72A-Rab8a proteins in the cytosolic and membrane fraction of HEK293 cells. PD, Parkinson's disease.
Figure 6—figure supplement 1. Rab10/12-GDI interactions.
(A) HA-Rab10 constructs (wt, T73A, T73E) were expressed in HEK293 cells and lysates subjected to α-HA immunoprecipitation before western blotting. (B) Same as (A) using HA-Rab12 (wt, S106A, S106E). wt, wild type.